Richard Bell
Deakin University
107 Papers
690 Citations
Richard Bell is an academic researcher from Deakin University. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 32, co-authored 107 publications. Previous affiliations of Richard Bell include Geelong Hospital & Geelong Football Club.
Chat about Author
Papers
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian E. Smith,Marion Procter,Richard D. Gelber,Sebastien Guillaume,A. Feyereislova,Mitch Dowsett,Aron Goldhirsch,Michael Untch,Gabriella Mariani,José Baselga,Manfred Kaufmann,David Cameron,Richard Bell,Jonas Bergh,Robert E. Coleman,Andrew M Wardley,Nadia Harbeck,Roberto Ivan Lopez,Peter Mallmann,Karen A. Gelmon,Nicholas Wilcken,Erik Wist,Pedro Sánchez Rovira,Martine Piccart-Gebhart +23 more
TL;DR: The results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years, and the emergence of this benefit after only 2 years reinforces the importance of trastizumab in the treatment of women with HER2-positive early breast cancer.
1.6K
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron,Martine Piccart-Gebhart,Richard D. Gelber,Richard D. Gelber,Marion Procter,Aron Goldhirsch,Evandro de Azambuja,Gilberto de Castro,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,N. Al-Sakaff,S. Lauer,Eleanor McFadden,Brian Leyland-Jones,Richard Bell,Mitch Dowsett,Christian Jackisch +18 more
TL;DR: 1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival, compared with observation.
925
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Pierre Major,Alain Lortholary,J. Hon,E Abdi,Gordon B. Mills,H D Menssen,F Yunus,Richard Bell,Jean-Jacques Body,E Quebe-Fehling,John W. Seaman +10 more
TL;DR: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
839
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman,Helen Marshall,David Cameron,D. Dodwell,Roger Burkinshaw,M. Keane,M. Gil,Stephen Houston,Robert Grieve,Peter Barrett-Lee,Diana Ritchie,Julia Pugh,Claire Gaunt,Una Rea,Jennifer Peterson,Claire Davies,Victoria Hiley,Walter M Gregory,Richard Bell +18 more
TL;DR: The routine use of zoledronic acid in the adjuvant management of breast cancer is not supported, and a prespecified boundary for lack of benefit had been crossed.